Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enterogermina versus placebo for small intestinal bacterial overgrowth
2018-001355-12Phase 4Terminated
- Sponsor
- Sanofi
- Start
- Oct 2020
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in blind loop syndrome (BLS) comparing Enterogermina with Placebo (2 arms). Primary endpoint: SIBO eradication. Started Oct 2020; status: terminated.
02
Drugs
bacillus clausii
03
Conditions
blind loop syndrome (BLS)
Beyond the preview
Go deeper on 2018-001355-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001355-12.